[131I]-IR199

[131I]-IR199 is a radiopharmaceutical consisting of the Claudin 18.2 (CLDN18.2)-targeting ligand IR199 labeled with the radioisotope Iodine-131. Developed by researchers at Huashan Hospital, Fudan University, it is designed to target CLDN18.2-expressing tumors, such as gastric and pancreatic cancers. The agent is used in clinical studies to evaluate human biodistribution and radiation dosimetry, often following initial screening with the Gallium-68 labeled analog, [68Ga]-IR199. While Iodine-131 is a beta-emitter commonly used for targeted radionuclide therapy, this specific study focuses on characterizing its pharmacokinetics and safety profile in patients with CLDN18.2-positive malignancies.

Other names

[131I]IR199131I-IR199Iodine-131 IR199Iodine131 IR199Iodine 131 IR199